Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates

Medicinal Research Reviews

Volumn 36, Issue 1, 2016, Pages 32-91

  Xiao, Zhiyan ^a   Morris Natschke, Susan L ^b   Lee, Kuo Hsiung ^b,c  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Anticancer drugs; Lead optimization; Natural products

Indexed keywords

9,10 DIDEHYDROEPOTHILONE D; ABEXINOSTAT; ACRONINE; ANTINEOPLASTIC AGENT; BELORANIB; BROSTALLICIN; DACINOSTAT; ENTINOSTAT; EPOTHILONE D; EXATECAN; FLUOXYMESTERONE; GIVINOSTAT; IDRONOXIL; METHOTREXATE; MOCETINOSTAT; NATURAL PRODUCT; OBATOCLAX; PACLITAXEL; PANOBINOSTAT; PLINABULIN; QUISINOSTAT; RAPAMYCIN; ROSCOVITINE; SAGOPILONE; SOBLIDOTIN; TAFLUPOSIDE; TERAMEPROCOL; UNINDEXED DRUG; VADIMEZAN; VINBLASTINE; BIOLOGICAL PRODUCT;

ARTICLE; DRUG EFFICACY; DRUG SOLUBILITY; MEDICINAL CHEMISTRY; MOLECULARLY TARGETED THERAPY; PHARMACOPHORE; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG STABILITY; HUMAN; MOUSE; NEOPLASMS; PROCEDURES; SOLUBILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG DISCOVERY; DRUG STABILITY; HUMANS; MICE; MOLECULAR STRUCTURE; NEOPLASMS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84951568012     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21377     Document Type: Article

References (270)

1. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep 2000;17:215-234.
2. Buss AD, Cox B, Waigh RD. Natural products as leads for new pharmaceuticals. In: Abraham DJ, Ed. Burger's Medicinal Chemistry and Drug Discovery 6th ed., Vol. 1: Drug Discovery. N J: Wiley, Hoboken; 2003. p 847-900.
3. Henkel T, Brunne RM, Muller H, Reichel F. Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew Chem Int Ed 1999;38:643-647.
4. Feher M, Schmidt JM. Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 2003;43:218-227.
5. Grabowski K, Schneider G. Properties and architecture of drugs and natural products revisited. Curr Chem Biol 2007;1:115-127.
6. Wetzel S, Schuffenhauer A, Roggo S, Ertl P, Waldmann H. Cheminformatic analysis of natural products and their chemical space. Chimia 2007;61:355-360.
7. Singh N, Guha R, Giulianotti MA, Pinilla C, Houghten RA, Medina-Franco JL. Chemoinformatic analysis of combinatorial libraries, drugs, natural products, and molecular libraries small molecule repository. J Chem Inf Model 2009;49:1010-1024.
8. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005;4:206-220.
9. Newman DJ. Natural products as leads to potential drugs: An old process or the new hope for drug discovery? J Med Chem 2008;51:2589-2599.
10. Nicolaou KC, Chen JS, Dalley SM. From nature to the laboratory and into the clinic. Bioorg Med Chem 2009;17:2290-2303.
11. Kinghorn AD, Pan L, Fletcher JN, Chai H. The relevance of higher plants in lead compound discovery programs. J Nat Prod 2011;74:1539-1555.
12. Mishra BB, Tiwari VK. Natural products: An evolving role in future drug discovery. Eur J Med Chem 2011;46:4769-4807.
13. Cragg GM, Newman DJ. Natural products: A continuing source of novel drug leads. Biochim Biophys Acta Gen Subj 2013;1830:3670-3695.
14. Cragg GM, Newman DJ, Snader KM. Natural products in drug discovery and development. J Nat Prod 1997;60:52-60.
15. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-1037.
16. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007;70:461-477.
17. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012;75:311-335.
18. Shu Y-Z. Recent natural products based drug development: A pharmaceutical industry perspective. J Nat Prod 1998;61:1053-1071.
19. Butler MS. Natural products to drugs: Natural product derived compounds in clinical trials. Nat Prod Rep 2005;22:162-195.
20. Butler MS. Natural products to drugs: Natural product-derived compounds in clinical trials. Nat Prod Rep 2008;25:475-516.
21. Mann J. Natural products in cancer chemotherapy: Past, present and future. Nat Rev Cancer 2002;2:143-148.
22. Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol 2007;9:767-776.
23. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anticancer agents. Chem Rev 2009;109:3012-3043.
24. Das B, Satyalakshmi G. Natural products based anticancer agents. Mini-Rev Org Chem 2012;9:169-177.
25. Cragg GM, Newman DJ. A tale of two tumor targets: Topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy. J Nat Prod 2004;67:232-244.
26. Oberlies NH, Kroll DJ. Camptothecin and Taxol: Historic achievements in natural products research. J Nat Prod 2004;67:129-135.
27. Altmann K-H, Gertsch J. Anticancer agents from nature-Natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Res 2007;24:327-357.
28. Wall ME. Camptothecin and Taxol: Discovery to clinic. Med Res Rev 2008;18:299-314.
29. Kingston DGI. Tubulin-interactive natural products as anticancer agents. J Nat Prod 2009;72:507-515.
30. Salvador JAR, Carvalho JFS, Neves MAC, Silvestre SM, Leitao AJ, Silva MMC, Sa eMML. Anticancer steroids: Linking natural and semi-synthetic compounds. Nat Prod Rep 2013;30:324-374.
31. Cragg GM, Kingston DGI, Newman DJ, Eds. Anticancer Agents From Natural Products. Londo n, UK: CRC Press, Taylor & Francis Group; 2005.
32. Cragg GM, Kingston DGI, Newman DJ, Eds. Anticancer Agents From Natural Products. 2nd ed. London, UK: CRC Press, Taylor & Francis Group; 2011.
33. Cragg GM. Paclitaxel (Taxol): A success story with valuable lessons for natural product drug discovery and development. Med Res Rev 1998;18:315-331.
34. Itokawa H, Lee KH, Eds. Taxus-The genus Taxus. London, UK: CRC Press, Taylor & Francis Group; 2003, and literature cited therein.
35. Chashoo G, Singh SK. Holistic molecular approaches for anticancer therapy. J Biomed Pharm Res 2012;1:5-29.
36. Cohen SS, Flaks JG, Barner HD, Loeb MR, Lichtenstein J. The mode of action of 5-fluorouracil and its derivatives. Proc Natl Acad Sci U S A 1958;44:1004-1012.
37. Burchenal JH, Murphy ML, Ellison RR, Sykes MP, Tan TC, Leone LA, Karnofsky DA, Craver LF, Dargeon HW, Rhoads CP. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 1953;8:965-999.
38. Clarke DA, Hamilton LD, Philips FS, Sternberg SS. Effects of thioguanine in mammals. Cancer 1956;9:1092-1101.
39. Chu MY, Fischer GA. A proposed mechanism of action of 1-β-D-arabinofuranosylcytosine as an inhibitor of the growth of leukemic cells. Biochem Pharmacol 1962;11:423-430.
40. Cihak A, Vesely J, Hynie S. Transformation and metabolic effects of 5-aza-2'-deoxycytidine in mice. Biochem Pharmacol 1980;29:2929-2932.
41. Nelson MC, Hogan DK. The role of cladribine in the treatment of lymphoid malignancies. Oncol Nurs Forum 1995;22:1395-1400.
42. Qian M, Wang X, Shanmuganathan K, Chu CK, Gallo JM. Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats. Cancer Chemother Pharmacol 1994;33:484-488.
43. Takahashi T, Kanazawa J, Akinaga S, Tamaoki T, Okabe M. Antitumor activity of 2-chloro-9-(2- deoxy-2-fluoro-β-D-arabinofuranosyl)adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Cancer Chemother Pharmacol 1999;43:233-240.
44. Hertz R, Li MC, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 1956;93:361-366.
45. Horn Y, Halden A, Gordan GS. The platelet-stimulating effects of 7-beta, 17-alpha-dimethyltestosterone (calusterone). Blood 1972;40:684-687.
46. Kennedy BJ. Fluoxymesterone in the treatment of advanced breast cancer. Cancer 1957;10:813-818.
47. Goodin S. Novel cytotoxic agents: Epothilones. Am J Health Syst Pharm 2008;65:S10-S15.
48. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;5:1429-1437.
49. Conlin A, Fornier M, Hudis C, Kar S, Kirkpatrick P. Ixabepilone. Nat Rev Drug Discov 2007;6:953-954.
50. Talpir R, Benayahu Y, Kashman Y, Pannell L, Schleyer M. Hemiasterlin and geodiamolide TA; two new cytotoxic peptides from the marine sponge Hemiasterella minor (Kirkpatrick). Tetrahedron Lett 1994;35:4453-4456.
51. Anderson HJ, Coleman JE, Andersen RJ, Roberge M. Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother Pharmacol 1997;39:223-226.
52. Andersen RJ, Williams DE, Strangman WK, Roberge M. HTI-286 (Taltobulin), a synthetic analog of the antitumor natural product Hemiasterlin. In: Cragg GM, Kingston DGI, Newman DJ, Eds. Anticancer Agents From Natural Products. 2nd ed. Londo n, UK: CRC Press, Taylor & Francis Group; 2011. p. 347-362.
53. Mallinson J, Collins I. Macrocycles in new drug discovery. Future Med Chem 2012;4:1409-1438.
54. Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R, Pazdur R. FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010;15:428-435.
55. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-2347.
56. Sedrani R, Cottens S, Kallen J, Schuler W. Chemical modification of rapamycin: The discovery of SDZ RAD. Transplant Proc 1998;30:2192-2194.
57. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW, Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26:361-367.
58. Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchiya H, Takahashi Y, Masuma R. A new alkaloid AM-2282 of Streptomyces origin taxonomy, fermentation, isolation and preliminary characterization. J Antibiot 1977;30:275-282.
59. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-132.
60. Zaugg K, Rocha S, Resch H, Hegyi I, Oehler C, Glanzmann C, Fabbro D, Bodis S, Pruschy M. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res 2001;61:732-738.
61. Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 2003;36:417-425.
62. Veselý J, Havlíček L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato JY, Detivaud L, Leclerc S, Meijer L. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994;224:771-786.
63. Havlíček L, Hanuš J, Veselý J, Leclerc S, Meijer L, Shaw G, Strnad M, Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of Olomoucine and related compounds. J Med Chem 1997;40:408-412.
64. Harmon AD, Weiss U. The structure of Rohiturine, the main alkaloid of Amoora rohituka (Syn. Aphanafhxis polystachya) (Meliaceae). Tetrahedron Lett 1979;20:721-724.
65. Senderowicz AM. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 1999;17:313-320.
66. Kase H, Iwahashi K, Matsuda Y. K-252a, a potent inhibitor of protein kinase C from microbial origin. J Antibiot 1986;39:1059-1065.
67. Prudhomme M. Biological targets of antitumor indolocarbazoles bearing a sugar moiety. Curr Med Chem Anticancer Agents 2004;4:509-521.
68. Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010;115:1425-1432.
69. Mahoney S, Rfuso F, Rogers P, Hisheh S, Rown DB, Millward M, Dharmarajan, Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines. J Biosci 2012;37:73-84.
70. Howes JB, de Souza PL, West L, Huang LJ, Howes LG, Pharmacokinetics of phenoxodiol, a novel isoflavone, following intravenous administration to patients with advanced cancer. BMC Clin Pharmacol 2011;11:1.
71. Saif MW, Tytler E, Lansigan F, Brown DM, Husband AJ. Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. Expert Opin Investig Drugs 2009;18:469-479.
72. Wang X, McKernan R, Kim KH, Alvero AB, Whiting A, Thompson JA, Mor G, Saif MW, Husband AJ, Brown DM, Tytler EM. Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. Anticancer Drugs 2011;22:719-731.
73. McMorris TC, Kelner MJ, Wang W, Estes LA, Montoya MA, Taetle R. Structure-activity relationship of illudins: Analogs with improved therapeutic index. J Org Chem 1992;57:6876-6883.
74. McMorris TC, Staake MD, Kelner MJ. Synthesis and biological activity of enantiomers of antitumor irofulven. J Org Chem 2004;69:619-623.
75. Wang Y, Wiltshire T, Senft J, Reed E, Wang W. Irofulven induces replication-dependent CHK2 activation related to p53 status. Biochem Pharmacol 2007;73:469-480.
76. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-557.
77. Chun E, Han CK, Yoon JH, Sim TB, Kim YK, Lee KY. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int J Cancer 2005;114:124-130.
78. Kim EJ, Shin WH. General pharmacology of CKD-732, a new anticancer agent: Effects on central nervous, cardiovascular, and respiratory system. Biol Pharm Bull 2005;28:217-223.
79. Bernier SG, Lazarus DD, Clark E, Doyle B, Labenski MT, Thompson CD, Westlin WF, Hannig G. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci USA 2004;101:10768-10773.
80. Hannig G, Lazarus DD, Bernier SG, Karp RM, Lorusso J, Qiu D, Labenski MT, Wakefield JD, Thompson CD, Westlin WF. Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458. Int J Oncol 2006;28:955-963.
81. Tillequin F. Rutaceous alkaloids as models for the design of novel antitumor drugs. Phytochem Rev 2007;6:65-79.
82. Léonce S, Kraus-Berthier L, Golsteyn RM, David-Cordonnier M-H, Tardy C, Lansiaux A, Poindessous V, Larsen AK, Pierré A, Generation of replication-dependent double-strand breaks by the novel N2-G-alkylator S23906-1. Cancer Res 2006;66:7203-7210.
83. Fürstner A, Chemistry and biology of roseophilin and the prodigiosin alkaloids: A survey of the last 2500 years. Angew Chem Int Ed 2003;42:3582-3603.
84. Murthy MSR, Steenaart NAE, Johnson RA, Shore GC. Prodigiosin-derivatives as neoplastic and anti-viral agents. PCT Int Appl WO 2001055131, 2001; 267 pp.
85. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006;13:1419-1421.
86. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Bélec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, Shore GC. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007;104:19512-19517.
87. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK, Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007;109:5430-5438.
88. Bibby MC. Flavone acetic acid-An interesting novel therapeutic agent or just another disappointment? Br J Cancer 1991;63:3-5.
89. Rewcastle GW, Atwell GJ, Baguley BC, Calveley SB, Denny WA. Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. J Med Chem 1989;32:793-799.
90. Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC, Denny WA. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic. J Med Chem 1991;34:217-222.
91. Wallace A, LaRosa DF, Kapoor V, Sun J, Cheng G, Jassar A, Blouin A, Ching LM, Albelda SM. The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. Cancer Res 2007;67:7011-7019.
92. McKeage MJ. The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin Invest Drugs 2008;17:23-29.
93. Yoshimura F, Rivkin A, Gabarda AE, Chou T-C, Dong H, Sukenick G, Morel FF, Taylor RE, Danishefsky SJ. Synthesis and conformational analysis of (E)-9, 10-dehydroepothilone B: A suggestive link between the chemistry and biology of epothilones. Angew Chem Int Ed 2003;42:2518-2521.
94. Rivkin A, Yoshimura F, Gabarda AE, Chou T-C, Dong H, Tong WP, Danishefsky SJ. Complex target-oriented total synthesis in the drug discovery process: The discovery of a highly promising family of second generation epothilones. J Am Chem Soc 2003;125:2899-2901.
95. Kanoh K, Kohno S, Asari T, Harada T, Katada J, Muramatsu M, Kawashima H, Sekiya H, Uno I. (-)-Phenylahistin: A new mammalian cell cycle inhibitor produced by aspergillus ustus. Bioorg Med Chem Lett 1997;7:2847-2852.
96. Kanoh K, Kohno S, Katada J, Hayash Y, Muramatsu M, Uno I. Antitumor activity of phenylahistin in vitro and in vivo. Biosci Biotechnol Biochem 1999;63:1130-1133.
97. Nicholson B, Lloyd GK, Miller BR, Palladino MA, Kiso Y, Hayashi Y, Neuteboom ST. NPI-2358 is a tubulin-depolymerizing agent: In-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drug 2006;17:25-31.
98. Borthwick AD. 2, 5-Diketopiperazines: Synthesis, reactions, medicinal chemistry, and bioactive natural products. Chem Rev 2012;112:3641-3716.
99. Roussi F, Guéritte F, Fahy J. The vinca alkaloids. In: Cragg GM, Kingston DGI, Newman DJ, Eds. Anticancer Agents From Natural Products. 2nd ed. Londo n, UK: CRC Press, Taylor & Francis Group; 2011. p 177-198.
100. Barnett CJ, Cullinan GJ, Gerzon K, Hoying RC, Jones WE, Newlon WM, Poore GA, Robison RL, Sweeney MJ. Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetyl vinblastine amide (vindesine) sulfate. J Med Chem 1978;21:88-96.
101. Joel S. The comparative clinical pharmacology of vincristine and vindesine: Does vindesine offer any advantage in clinical use? Cancer Treat Rev 1995;21:513-525.
102. Mano M. Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy. Cancer Treat Rev 2006;32:106-118.
103. Fahy J, Duflos A, Ribet J-P, Jacquesy J-C, Berrier C, Jouannetaud M-P, Zunino F. Vinca alkaloids in superacidic media: A method for creating a new family of antitumor derivatives. J Am Chem Soc 1997;119:8576-8577.
104. Kruczynski A, Barret JM, Etiévant C, Colpaert F, Fahy J, Hill BT. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 1998;55:635-648.
105. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969;11:1101-1110.
106. Bonfante V, Bonadonna G, Villani F, Martini A. Preliminary clinical experience with 4-epidoxorubicin in advanced human neoplasia. Recent Results Cancer Res 1980;74:192-199.
107. Miller AA, Salewski E. Prospects for pirarubicin. Med Pediatr Oncol 1994;22:261-268.
108. Kuznetsov DD, Alsikafi NF, O'Connor RC, Steinberg GD. Intravesical valrubicin in the treatment of carcinoma in situ of the bladder. Expert Opin Pharmacother 2001;2:1009-1013.
109. Cortés-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 2007;7:56-60.
110. Seidlova-Massinova V, Malinsky J, Santavy F. The biological effect of some podophyllotoxin compounds and their dependence on chemical structure. J Natl Cancer Inst 1957;18:359-371.
111. Hande KR. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998;34:1514-1521.
112. Cragg GM, Newman DJ. Plants as a source of anticancer agents. J Ethnopharmacol 2005;100:72-79.
113. Sargent JM, Elgie AW, Williamson CJ, Hill BT. Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs 2003;14:467-473.
114. Arcamone F-M, Sabarubicin . Anthracycline chemistry and biology II. Top Curr Chem 2008;283:171-189.
115. Broggini M. Nemorubicin. Anthracycline chemistry and biology II. Top Curr Chem 2008;283:191-206.
116. Gnabre JN, Brady JN, Clanton DJ, Ito Y, Dittmer J, Bates RB, Huang RC. Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans. Proc Natl Acad Sci USA 1995;92:11239-11243.
117. Hwu JR, Tseng WN, Gnabre JG, Giza P, Huang RC. Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of Tat-regulated HIV transactivation. J Med Chem 1998;41:2994-3000.
118. Chen H, Teng L, Li J, Park R, Mold DE, Gnabre J, Hwu JR, Tseng WN, Huang RC. Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. J Med Chem 1998;41:3001-3007.
119. Craigol J, Callahan M, Huang RC, DeLucia A. Inhibition of human papillomavirus type 16 gene expression by nordihydroguaiaretic acid plant lignin derivatives. Antiviral Res 2000;47:19-28.
120. Heller JD, Kuo J, Wu TC, Kast WM, Huang RCC. Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo. Cancer Res 2001;61:5499-5504.
121. Lopez RA, Goodman AB, Rhodes M, Blomberg JAL, Heller J. The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration. Anticancer Drugs 2007;18:933-939.
122. Mishra RC. Microtubule binding natural substances in cancer chemotherapy. In: Tiwari VK, Mishra BB, Eds. Opportunity, Challenge and Scope of Natural Products in Medicinal Chemistry. Kerala, India: Research Signpost; 2011. p 269-282.
123. Kingston DGI. Taxol: The chemistry and structure-activity relationships of a novel anticancer agent. Trends Biotechnol 1994;12:222-227.
124. Kingston DGI. Taxol and its Analogs. In: Cragg GM, Kingston DGI, Newman DJ, Eds. Anticancer Agents From Natural Products. 2nd ed. Londo n, UK: CRC Press, Taylor & Francis Group; 2011. p 123-175.
125. Yared JA, Tkaczuk KHR. Update on taxane development: New analogs and new formulations. Drug Des Dev Ther 2012;6:371-384.
126. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: Paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993;19:351-386.
127. Malhotra M, Dhingra R, Sharma T, Deep A, Narasimhan B, Phogat P, Sharma PC. Cabazitaxel: A novel drug for hormone-refractory prostate cancer. Mini-Rev Med Chem 2013;13:915-920.
128. Cragg GM, Grothaus PG, Newman DJ. New horizons for old drugs and drug leads. J Nat Prod 2014;77:703-723.
129. Kingston DGI, Snyder JP. The quest for a simple bioactive analog of paclitaxel as a potential anticancer agent. Acc Chem Res 2014;47:2682-2691.
130. Goodin S, Kane MP, Rubin EH. Epothilones: Mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-2025.
131. Höfle G, Reichenbach H. Epothilone, a myxobacterial metabolite with promising antitumor activity. In: Cragg GM, Kingston DGI, Newman DJ, Eds. Anticancer Agents From Natural Products. 2nd ed. Lond on, UK: CRC Press, Taylor & Francis Group; 2011. p 513-573.
132. Kaiser S, Muller JJ, Froehlich PE, Cristina Baggio Gnoatto S, Bergold AM. From bacteria to antineoplastic: Epothilones, a successful history. Anticancer Agents Med Chem 2013;13:1057-1068.
133. Rivkin A, Yoshimura F, Fumihiko G, Gabarda AE, Cho YS, Chou T-C, Dong H, Danishefsky SJ. Discovery of (E)-9, 10-dehydroepothilones through chemical synthesis: On the emergence of 26-trifluoro-(E)-9, 10-dehydro-12, 13-desoxyepothilone B as a promising anticancer drug candidate. J Am Chem Soc 2004;126:10913-10922.
134. Rivkin A, Chou TC, Danishefsky SJ. On the remarkable antitumor properties of fludelone: How we got there. Angew Chem Int Ed Engl 2005;44:2838-2850.
135. Chou TC, Zhang X, Zhong ZY, Li Y, Feng L, Eng S, Myles DR, Johnson R Jr, Wu N, Yin YI, Wilson RM, Danishefsky SJ. Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones. Proc Natl Acad Sci USA 2008;105:13157-13162.
136. Trivedi M, Budihardjo I, Loureiro K, Reid TR, Ma JD. Epothilones: A novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol 2008;4:483-500.
137. Nicolaou KC, King NP, Finlay MRV, He Y, Roschangar F, Vourloumis D, Vallberg H, Sarabia F, Ninkovic S, Hepworth D. Total synthesis of Epothilone E and related side-chain modified analogues via a stille coupling based strategy. Bioorg Med Chem 1999;7:665-697.
138. Galmarini CM. Sagopilone, a microtubule stabilizer for the potential treatment of cancer. Curr Opin Investig Drugs 2009;10:1359-1371.
139. Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 2007;18:v9-v15.
140. Pettit GR, Kamano Y, Herald CL, Tuinman AA, Boettner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB, Bontems RJ. The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10. J Am Chem Soc 1987;109:6883-6885.
141. Bai RL, Pettit GR, Hamel E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 1990;265:17141-17149.
142. Bai R, Friedman SJ, Pettit GR, Hamel E. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol 1992;43:2637-2645.
143. Flahive E, Srirangam J. The dolastatins: Novel antitumor agents from Dolabella auricularia. In: Cragg GM, Kingston DGI, Newman DJ, Eds. Anticancer Agents From Natural Products. 2nd ed. Lond on, UK: CRC Press, Taylor & Francis Group; 2011. p 263-289.
144. Miyazaki K, Kobayashi M, Natsume T, Gondo M, Mikami T, Sakakibara K, Tsukagoshi S. Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem Pharm Bull 1995;43:1706-1718.
145. Supko JG, Lynch TJ, Clark JW, Fram R, Allen LF, Velagapudi R, Kufe DW, Eder JP Jr. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Cancer Chemother Pharmacol 2000;46:319-328.
146. Ebbinghaus S, Hersh E, Cunningham CC, O'Day S, McDermott D, Stephenson J, Richards DA, Eckardt J, Haider OL, Hammond LA. Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma. J Clin Oncol 2004;22:7530-7530.
147. Naumovski L, Junutula JR. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 2010;12:248-257.
148. Abolmaali SS, Tamaddon AM, Dinarvand R. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharm 2013;71:1115-1130.
149. O'Connor OA. Pralatrexate: An emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 2006;18:591-597.
150. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res 1991;51:5579-5586.
151. Manegold C. Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma. Semin Oncol 2003;30:32-36.
152. Veber DF, Holly FW, Paleveda WJ, Nutt RF, Bergstrand SJ, Torchiana M, Glitzer MS, Saperstein R, Hirschmann R. Conformationally restricted bicyclic analogs of somatostatin. Proc Natl Acad Sci USA 1978;75:2636-2640.
153. Sideris L, Dube P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist 2012;17:747-755.
154. Melen-Mucha G, Lawnicka H, Kierszniewska-Stepien D, Komorowski J, Stepien H. The place of somatostatin analogs in the diagnosis and treatment of the neuroendocrine glands tumors. Front Anticancer Drug Discov 2010;1:241-272.
155. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990;265:17174-17179.
156. Stowell JC, Huot RI, Voast LV. The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells. J Med Chem 1996;38:1411-1413.
157. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-193.
158. Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K, Diamantidis G, France D, Green MA, Howell KL, Kashi R, Kwon P, Lassota P, Martin MS, Mou Y, Perez LB, Sharma S, Smith T, Sorensen E, Taplin F, Trogani N, Versace RW, Walker H, Weltchek-Engler S, Wood A, Wu A, Atadja P. N-Hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: Discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl) ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 2003;46:4609-4624.
159. Catley L, Weisberg E, Tai Y-T, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003;102:2615-2622.
160. Revill P, Mealy N, Serradell N, Bolos J, Rosa E. Panobinostat. Drugs Future 2007;32:315-322.
161. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2:721-728.
162. Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A, Introna M, Barbui T, Golay J, Rambaldi A. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008;22:740-747.
163. Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR, Dalrymple SA. CRA-024781: A novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther 2006;5:1309-1317.
164. Tong W-G, Wei Y, Stevenson W, Kuang S-Q, Fang Z, Zhang M, Arts J, Garcia-Manero G. Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Leukemia Res 2010;34:221-228.
165. Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases-The development of an anticancer agent. Int J Biochem Cell Biol 2007;39:1388-1405.
166. Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, MacLean M, King S, Brown S, Reid GK, Li Z, Kalita AM, Laille EJ, Besterman JM, Martell RE, Carducci MA. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26:1940-1947.
167. Lane M, Kelly MG. The antitumor activity of 5-bis-2'-chlorethyl)-aminouracil (uracil mustard). Cancer Res 1960;20:511-517.
168. Kennedy BJ, Torkelson JL, Torlakovic E. Uracil mustard revisited. Cancer 1999;85:2265-2272.
169. Nilsson T, Muntzing J. Histochemical and biochemical investigation of advanced prostatic carcinoma treated with estramustine phosphate, Estracyt. Scand J Urol Nephrol 1973;7:18-22.
170. Arcamone F, Penco S, Orezzi P, Nicolella V, Pirelli A. Structure and synthesis of distamycin A. Nature 1964;203:1064-1065.
171. Baraldi PG, Zaid AN, Preti D, Fruttarolo F, Tabrizi MA, Iaconinoto A, Pavani MG, Carrion MD, Cara CL, Romagnoli R. Hybrid molecules based on distamycin A as potential antitumor agents. Arkivoc 2006;7:20-34.
172. Weiss GR, Poggesi I, Rocchetti M, DeMaria D, Mooneyham T, Reilly D, Vitek LV, Whaley F, Patricia E, Von Hoff DD, O'Dwyer P. A phase I and pharmacokinetic study of tallimustine [PNU152241 (FCE 24517)] in patients with advanced cancer. Clin Cancer Res 1998;4:53-59.
173. Geroni C, Marchini S, Cozzi P, Galliera E, Ragg E, Colombo T, Battaglia R, Howard M, D'Incalci M, Broggini M. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res 2002;62:2332-2336.
174. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AI, Sim GA. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate. J Am Chem Soc 1966;88:3888-3890.
175. Rahier NJ, Thomas CJ, Hecht SM. Camptothecin and its analogs. In: Cragg GM, Kingston DGI, Newman DJ, Eds. Anticancer Agents From Natural Products. 1st ed. Lond on, UK: CRC Press, Taylor & Francis Group; 2005. p 5-21.
176. Mattern MR, Hofmann GA, McCabe FL, Johnson RK. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 1991;51:5813-5816.
177. Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY, Jew SS, Park JG, Hong CI. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res 1998;21:581-590.
178. Mitsui I, Kumazawa E, Hirota Y, Aonuma M, Sugimori M, Ohsuki S, Uoto K, Ejima A, Terasawa H, Sato K. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995;86:776-782.
179. Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, Sivret J, Rusk J, Barrett E. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol 2004;93:229-232.
180. Beretta GL, Zuco V, De Cesare M, Perego P, Zaffaroni N. Namitecan: A hydrophilic camptothecin with a promising preclinical profile. Curr Med Chem 2012;19:3488-3501.
181. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999;96:10403-10408.
182. Elofsson M, Splittgerber U, Myung J, Mohan R, Crews CM. Towards subunit-specific proteasome inhibitors: Synthesis and evaluation of peptide α', β'-epoxyketones. Chem Biol 1999;6:811-822.
183. Kortuem KM, Stewart AK. Carfilzomib. Blood 2013;121:893-897.
184. Halford B. Carfilzomib: From discovery to drug. C&EN 2012;90:34-35.
185. Schulte TW, Akinaga S, Soga S, Sullivan W, Stensgard B, Toft D, Neckers LM. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperon 1998;3:100-108.
186. Snader KM. Benzoquinone ansamycins. In: Cragg GM, Kingston DGI, Newman DJ, Eds. Anticancer agents from natural products. 1st ed. Londo n, UK: CRC Press, Taylor & Francis Group; 2005. p 339-356.
187. Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG. Tanespimycin as antitumor therapy. Clin Lymphoma Myeloma Leuk 2011;11:17-22.
188. Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010;24:699-705.
189. Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, Georges AT, Grenier L, Pak RH, Patterson J, Sydor JR, Tibbitts TT, Tong JK, Adams J, Palombella VJ. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 2006;49:4606-4615.
190. Takatsu T, Ohtsuki M, Muramatsu A, Enokita R, Kurakata SI. Reblastatin, a novel benzenoid ansamycin-type cell cycle inhibitor. J Antibiot 2000;53:1310-1312.
191. Bush JA, Long BH, Catino JJ, Bradner WT, Tomita K. Production and biological activity of rebeccamycin, a novel antitumor agent. J Antibiot (Tokyo) 1987;40:668-678.
192. Anizon F, Belin L, Moreau P, Sancelme M, Voldoire A, Prudhomme M, Ollier M, Sevère D, Riou JF, Bailly C, Fabbro D, Meyer T. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J Med Chem 1997;40:3456-3465.
193. Schwandt A, Mekhail T, Halmos B, O'Brien T, Ma PC, Fu P, Ivy P, Dowlati A. Phase-II trial of rebeccamycin analog, a dual topoisomerase-<>I and -<>II inhibitor, in relapsed "sensitive" small cell lung cancer. J Thorac Oncol 2012;7:751-754.
194. Kohn KW, Waring MJ, Glaubiger D, Friedman CA. Intercalative binding of ellipticine to DNA. Cancer Res 1975;35:71-76.
195. Rouëssé J, Spielmann M, Turpin F, Le Chevalier T, Azab M, Mondésir JM. Phase II study of elliptinium acetate salvage treatment of advanced breast cancer. Eur J Cancer 1993;29:856-859.
196. Khayat D, Borel C, Azab M, Paraisot D, Malaurie E, Bouloux C, Weil M. Phase I study of datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion. Cancer Chemother Pharmacol 1992;30:226-228.
197. Kattan J, Durand M, Droz JP, Mahjoubi M, Marino JP, Azab M. Phase I study of retelliptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule. Am J Clin Oncol 1994;17:242-245.
198. Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 2002;43:1763-1768.
199. Ji XJ, Zhang FR. Studies on antineoplastic action of indirubin derivatives and analogues and their structure-activity relationship. Acta Pharm Sin 1985;20:137-139.
200. Ji XJ, Liu XM, Li K, Chen RH, Wang LG. Pharmacological studies of meisoindigo: Absorption and mechanism of action. Biomed Environ Sci 1991;4:332-337.
201. Onoda T, Iinuma H, Sasaki Y, Hamada M, Isshiki IC, Naganawa H, Takeuchi T, Tatsuta R, Umezawa R. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. J Nat Prod 1989;52:1252-1257.
202. Onoda T, Isshiki K, Takeuchi T, Tatsuta K, Umezawa K. Inhibition of tyrosine kinase and epidermal growth factor receptor internalization by lavendustin A methyl ester in cultured A431 cells. Drugs Exp Clin Res 1990;16:249-253.
203. Nussbaumer P, Winiski AP, Cammisuli S, Hiestand P, Weckbecker G, Stutzt A. Novel antiproliferative agents derived from lavendustin A. J Med Chem 1994;37:4079-4084.
204. Nussbaumer P, Winiski AP. Structure-activity relationship studies on a novel class of antiproliferative agents derived from lavendustin A. Part I: Ring A modifications. Bioorg Med Chem 2008;16:7552-7560.
205. Medina J, Picarles V, Greiner B, Elsaesser C, Kolopp M, Mahl A, Roman D, Vogel B, Nussbaumer P, Winiski A, Meingassner J, Fraissinette Ade B. LAV694, a new antiproliferative agent showing improved skin tolerability vs. clinical standards for the treatment of actinic keratosis. Biochem Pharmacol 2003;66:1885-1895.
206. Kazerooni R, Conrad C, Baud C, Johansen M, Thapar N, Meyer C, Priebe W, Madden T. Phase I clinical pharmacokinetics of RTA 744: A blood brain barrier penetrating anthracycline active against high-grade glioma. J Clin Oncol 2007;25(18S):2045.
207. Sanda T, Kuwano T, Nakao S, Iida S, Ishida T, Komatsu H, Shudo K, Kuwano M, Ono M, Ueda R. Antimyeloma effects of a novel synthetic retinoid Am80 (tamibarotene) through inhibition of angiogenesis. Leukemia 2005;19:901-909.
208. Boehm MF, Zhang L, Zhi L, McClurg MR, Berger E, Wagoner M, Mais DE, Suto CM, Davies PJA, Heyman RA, Nadzant AM. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995;38:3146-3155.
209. Kroep JR, Gelderblom H. Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Invest Drugs 2009;18:69-75.
210. Lavergne O, Harnett J, Rolland A, Lanco C, Lesueur-Ginot L, Demarquay D, Huchet M, Coulomb H, Bigg DCH . BN 80927: A novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II. Bioorg Med Chem Lett 1999;9:2599-2602.
211. Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Camara J, Kasprzyk PG, Prévost G, Bigg DC. BN80927: A novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo. Cancer Res 2004;64:4942-4949.
212. Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nuñez G. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's Disease. J Biol Chem 2003;278:5509-5512.
213. Hisano G, Fidler IJ. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin. Cancer Immunol Immunother 1982;14:61-66.
214. Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 2009;9:1035-1049.
215. Blagg J. Structural alerts for toxicity. In: Abraham DJ, Rotella DP, Eds. Burger's Medicinal Chemistry, Drug Discovery, and Development, 7th ed. New York: John Wiley & Sons, Inc.; 2010. p 301-334.
216. Morrison RK, Brown DE, Oleson JJ, Cooney DA. Oral toxicology studies with lapachol. Toxicol Appl Pharm 1970;17:1-11.
217. Li Y, Sun X, LaMont JT, Pardee AB, Li CJ. Selective killing of cancer cells by β-lapachone: Direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA 2003;100:2674-2678.
218. Wu, K-M. A new classification of prodrugs: Regulatory perspectives. Pharmaceuticals 2009;2:77-81.
219. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-5947.
220. Sawada S, Okajima S, Aiyama R, Nokata K, Furuta T, Yokokura T, Sugino E, Yamaguchi K, Miyasaka T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: Carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull 1991;39:1446-1454.
221. Leuenroth S. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 2007;104:4389-4394.
222. Zhou Z-L, Yang Y-X, Ding J, Li Y-C, Miao Z-H. Triptolide: Structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat Prod Rep 2012;29:457-475.
223. Pettit GR, Sheo BS, Boyd MR, Hamel E. Antineoplastic Agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6. J Med Chem 1995;38:1666-1672.
224. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res 1999;19;189-195.
225. Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 2002;83:21-38.
226. Hori K, Saito S, Kubota K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 2002;86:1604-1614.
227. Kruczynski A, Pillon A, Créancier L, Vandenberghe I, Gomes B, Brel V, Fournier E, Annereau JP, Currie E, Guminski Y, Bonnet D, Bailly C, Guilbaud N. F14512, a polyamine-vectorized anticancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity. Leukemia 2013;27:2139-2148.
228. Bergenheim AT, Henriksson R. Pharmacokinetics and pharmacodynamics of estramustine phosphate. Clin Pharmacokinet 1998;34:163-172.
229. Simpson D, Wagstaff AJ. Estramustine phosphate sodium. Am J Cancer 2003;2:373-390.
230. Ang JE, Olmos D, Bono JSD . CYP17 blockade by abiraterone: Further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 2009;100:671-675.
231. Bollag W, Hartmann HR. Tumor inhibitory effects of a new fluorouracil derivative: 5'-Deoxy-5-fluorouridine. Eur J Cancer 1980;16:427-432.
232. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-297.
233. Grem JL, Cheson BD, King SA, Leyland-Jones B, Suffness M. Cephalotaxine esters: Anti-leukemic advance or therapeutic failure? J Natl Cancer Inst 1988;80(14):1095-1103.
234. Robin J, Dhal R, Dujardin G, Girodier L, Mevellec L, Poutot S. The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety. Tetrahedron Lett 1999;40:2931-2934.
235. Wach J-Y, Gademann K. Reduce to the maximum: Truncated natural products as powerful modulators of biological processes. Synlett 2012;23:163-170.
236. Hirata Y, Uemura D. Halichondrins-Antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986;58:701-710.
237. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991;266:15882-15889.
238. Aicher TD, Buszek KR, Fang FG, Forsyth CJ, Jung SH, Kishi Y, Matelich MC, Scola PM, Spero DM, Yoon SK. Total synthesis of halichondrin B and norhalichondrin B. J Am Chem Soc 1992;114:3162-3164.
239. Zheng W, Seletsky BM, Palme MH, Lydon PJ, Singer LA, Chase CE, Lemelin CA, Shen Y, Davis H, Tremblay L, Towle MJ, Salvato KA, Wels BF, Aalfs KK, Kishi Y, Littlefield BA, Yu MJ. Macrocyclic ketone analogues of halichondrin B. Bioorg Med Chem Lett 2004;14:5551-5554.
240. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsk BM, Palme MH, Habgood GJ, Singer LA, Dipietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001;61:1013-1021.
241. Choi H-W, Demeke D, Kang F-A, Kishi Y, Nakajima K, Nowak P, Wan Z-K, Xie C. Synthetic studies on the marine natural product halichondrins. Pure Appl Chem 2003;75:1-17.
242. Huyck TK, Gradishar W, Manuguid F, Kirkpatrick P. Eribulin mesylate. Nat Rev Drug Discovery 2011;10:173-174.
243. Rinehart KL. Antitumor compounds from tunicates. Med Res Rev 2000;20:1-27.
244. Corey EJ, Gin DY, Kania RS. Enantioselective total synthesis of ecteinascidin 743. J Am Chem Soc 1996;118:9202-9203.
245. Martinez EJ, Owa T, Schreiber SL, Corey EJ. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743. Proc Natl Acad Sci USA 1999;96:3496-3501.
246. Cuevas C, Pérez M, Martín MJ, Chicharro JL, Fernández-Rivas C, Flores M, Francesch A, Gallego P, Zarzuelo M, de la Calle F, García J, Polanco C, Rodríguez I, Manzanares I. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org Lett 2000;2:2545-2548.
247. Leal JF, García-Hernández V, Moneo V, Domingo A, Bueren-Calabuig JA, Negri A, Gago F, Guillén-Navarro MJ, Avilés P, Cuevas C, García-Fernández LF, Galmarini CM. Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. Biochem Pharmacol 2009;78:162-170.
248. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald III JH, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Baevsky M, Ballas LM, Hall SE, Winneroski LL, Faul MM. (S)-13-[(Dimethylamino)methyl]-10, 11, 14, 15-tetrahydro-4, 9:16, 21-dimetheno-1H, 13H-dibenzo[e, k]pyrrolo[3, 4-h][1, 4, 13]oxadiazacyclohexadecene-1, 3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase Cβ. J Med Chem 1996;39:2664-2671.
249. Faul, MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M, Acyclic N- (azacycloalkyl)bisindolylmaleimides: Isozyme selective inhibitors of PKCβ. Bioorg Med Chem Lett 2003;13:1857-1859.
250. Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL, Rosen ST. Enzastaurin (LY317615), a protein kinase CB inhibitor, inhibits the AKT pathway andinduces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006;5:1783-1789.
251. Schneider G, Neidhart W, Giller T, Schmid G. "Scaffold-hopping" by topological pharmacophore search: A contribution to virtual screening. Angew Chem Int Ed 1999;38:2894-2896.
252. Sekhon BS, Bimal N. Scaffold hopping in drug discovery. RGUHS J Pharm Sci 2012;2:10-16.
253. Sun H, Tawa G, Wallqvist A. Classification of scaffold-hopping approaches. Drug Discov Today 2012;17:310-324.
254. Lee K-H. Novel antitumor agents from higher plants. Med Res Rev 1999;19:569-596.
255. Lee K-H. Current developments in the discovery and design of new drug candidates from plant natural product leads. J Nat Prod 2004;67:273-283.
256. Itokawa H, Morris-Natschke SL, Akiyama T, Lee K-H. Plant-derived natural product research aimed at new drug discovery. J Nat Med 2008;62:263-280.
257. Lee K-H. Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach. J Nat Prod 2010;73:500-516.
258. Lee KH, Xiao Z. Antitumor agents 277. Podophyllotoxins and analogs. In: Cragg GM, Kingston DGI, Newman DJ, Eds. Anticancer Agents From Natural Products. 2nd ed. London, UK: CRC Press, Taylor & Francis Group; 2011. p 95-122, and literature cited therein.
259. Wang ZQ, Kuo YH, Schnur D, Bowen JP, Liu SY, Han FS, Chang JY, Cheng YC, Lee K-H. Antitumor agents. 113. New 4β-arylamino derivatives of 4'-O-demethylepipodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II. J Med Chem 1990;33:2660-2666.
260. Li L, Wang H-K, Kuo S-C, Wu T-S, Lednicer D, Lin CM, Hamel E, Lee K-H. Antitumor Agents. 150. 2', 3', 4', 5', 5, 6, 7-Substituted 2-phenyl-4-quinolones and related compounds: Their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem 1994;37:1126-1135.
261. Xia Y, Yang Z-Y, Xia P, Hackl T, Hamel E, Mauger A, Wu J-H, Lee K-H. Antitumor Agents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents. J Med Chem 2001;44:3932-3936.
262. Wang S-W, Pan S-L, Peng C-Y, Huang D-Y, Tsai A-C, Chang Y-L, Guh J-H, Kuo S-C, Lee K-H, Teng C-M. CHM-1 inhibits hepatocyte growth factor-induced invasion of SK-Hep-1 human hepatocellular carcinoma cells by suppressing matrix metalloproteinase-9 expression. Cancer Lett 2007;257:87-96.
263. Chou L-C, Chen C-T, Lee J-C, Way T-D, Huang C-H, Huang S-M, Teng C-M, Yamori T, Wu T-S, Sun C-M, Chien D-S, Qian K, Morris-Natschke SL, Lee K-H, Huang L-J, Kuo S-C. Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6, 7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent. J Med Chem 2010;53:1616-1626.
264. Ohtsu H, Xiao Z, Ishida J, Nagai M, Wang H-K, Itokawa H, Su C-Y, Shih C, Chiang T, Chang E, Lee Y, Tsai M-Y, Chang C, Lee K-H. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem 2002;45:5037-5042.
265. Ohtsu H, Itokawa H, Xiao Z, Su C-Y, Shih CCY, Chiang T, Chang E, Lee Y, Chiu S-Y, Chang C, Lee K-H. Antitumor agents 222. Synthesis and anti-androgen activity of new diarylheptanoids. Bioorg Med Chem 2003;11:5083-5090.
266. Lin L, Shi Q, Su C-Y, Shih CCY, Lee K-H. Antitumor agents 247. New 4-ethoxycarbonylethyl curcumin analogs as potential antiandrogenic agents. Bioorg Med Chem 2006;14:2527-2534.
267. Lin L, Shi Q, Nyarko AK, Bastow KF, Wu C-C, Su C-Y, Shih CCY, Lee K-H. Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J Med Chem 2006;49:3963-3972.
268. Wilson RM, Danishefsky SJ. Small molecule natural products in the discovery of therapeutic agents: The synthesis connection. J Org Chem 2006;71:8329-8351.
269. Over B, Wetzel S, Gruetter C, Nakai Y, Renner S, Rauh D, Waldmann H. Natural-product-derived fragments for fragment-based ligand discovery. Nat Chem 2013;5:21-28.
270. Lachance H, Wetzel S, Kumar K, Waldmann H. Charting, navigating, and populating natural product chemical space for drug discovery. J Med Chem 2012;55:5989-6001.